Journal Watch · Frontiers in Immunology · 2026

Clinical characteristics and decreased CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> regulatory T cells and IL-35 in pediatric immune thrombocytopenia in a single center.

The defective Treg/IL-35 axis appears to be a important component in ITP pathogenesis, identifying IL-35 as a promising therapeutic target.

Yang Y, Lu D, Wu B et al.Frontiers in Immunology4 min readPharma relevance 75/100

DOI: 10.3389/fimmu.2026.1782560PMID: 41884844Study type: clinical study

TL;DR

The defective Treg/IL-35 axis appears to be a important component in ITP pathogenesis, identifying IL-35 as a promising therapeutic target.

Key findings

  • Immunological analysis demonstrated an elevated CD8<sup>+</sup> T cell proportion (<i>p</i> = 0.001), a decreased Treg cell proportion (<i>p</i> = 0.018), and a reduced CD4<sup>+</sup>/CD8<sup>+</sup> ratio (<i>p</i> = 0.019) in pediatric ITP patients.
  • Cytokine profiling revealed significantly elevated levels of IL-4 (<i>p</i> = 0.039) and IL-10 (<i>p</i> = 0.025), alongside a marked reduction in IL-35 (<i>p</i> = 0.020).<h4>Conclusion</h4>Pediatric ITP demonstrates significant differences from adult ITP in age distribution, sex characteristics, and prognosis.
  • The underlying immune dysregulation involves decreased regulatory T cells, significantly reduced levels of their specific anti-inflammatory cytokine IL-35 and concomitant expansion of CD8<sup>+</sup> T cells.
  • The defective Treg/IL-35 axis appears to be a important component in ITP pathogenesis, identifying IL-35 as a promising therapeutic target.

Numbers at a glance (from the abstract)

51.67%12.08%19.35%24.58%61.11%91.67%89.58%2.01%99.17%8.3%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

A history of vaccination within 1-4 weeks prior to onset was reported in 12.08% of patients, predominantly in the <1 year group (19.35%), whereas 24.58% had a recent history of respiratory infection, most frequently in the 3-6 years group (61.11%). Bleeding manifestations were present in 91.67% of patients, primarily involving the skin and mucous membranes (89.58%), while visceral hemorrhage was rare (5 cases, 2.01%). At the 1-month follow-up, the overall response rate (complete or partial response) reached 99.17%. The long-term (3 years) follow-up revealed a chronic ITP rate of only 8.3%, significantly lower than that in adults. 220 patients (91.67%) received treatment, and treatment selection was age-dependent: the <1 year group primarily received IVIG, whereas the >3 years group more frequently received corticosteroid therapy.

Full abstract (original)

Background: <h4>Background</h4>Immune thrombocytopenia (ITP) exhibits distinct epidemiological characteristics in terms of age and sex distribution. In contrast to adult ITP, the clinical features and immunological mechanisms underlying pediatric ITP remain incompletely understood.<h4>Objective</h4>To analyze the clinical characteristics, treatment response and immunological profiles of newly diagnosed pediatric ITP patients, in order to provide a reference for clinical diagnosis and treatment.<h4>Methods</h4>This study enrolled 240 newly diagnosed pediatric ITP patients. Demographic characteristics, predisposing factors, clinical manifestations, treatment response, and prognosis were analyzed. Lymphocyte subsets were assessed by flow cytometry, and serum cytokine levels were measured using ELISA.<h4>Results</h4>The <1 year age group constituted the largest subgroup (51.67%). Gender distribution differed significantly across the age groups (<i>p</i> = 0.005), with a marked male predominance in <1 year group (male-to-female ratio: 2.35:1).

What they did: A history of vaccination within 1-4 weeks prior to onset was reported in 12.08% of patients, predominantly in the <1 year group (19.35%), whereas 24.58% had a recent history of respiratory infection, most frequently in the 3-6 years group (61.11%). Bleeding manifestations were present in 91.67% of patients, primarily involving the skin and mucous membranes (89.58%), while visceral hemorrhage was rare (5 cases, 2.01%). At the 1-month follow-up, the overall response rate (complete or partial response) reached 99.17%. The long-term (3 years) follow-up revealed a chronic ITP rate of only 8.3%, significantly lower than that in adults. 220 patients (91.67%) received treatment, and treatment selection was age-dependent: the <1 year group primarily received IVIG, whereas the >3 years group more frequently received corticosteroid therapy.

Results & conclusions: Immunological analysis demonstrated an elevated CD8<sup>+</sup> T cell proportion (<i>p</i> = 0.001), a decreased Treg cell proportion (<i>p</i> = 0.018), and a reduced CD4<sup>+</sup>/CD8<sup>+</sup> ratio (<i>p</i> = 0.019) in pediatric ITP patients. Cytokine profiling revealed significantly elevated levels of IL-4 (<i>p</i> = 0.039) and IL-10 (<i>p</i> = 0.025), alongside a marked reduction in IL-35 (<i>p</i> = 0.020).<h4>Conclusion</h4>Pediatric ITP demonstrates significant differences from adult ITP in age distribution, sex characteristics, and prognosis. The underlying immune dysregulation involves decreased regulatory T cells, significantly reduced levels of their specific anti-inflammatory cytokine IL-35 and concomitant expansion of CD8<sup>+</sup> T cells. The defective Treg/IL-35 axis appears to be a important component in ITP pathogenesis, identifying IL-35 as a promising therapeutic target.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1782560 · PubMed 41884844.

Why it matters for pharma & biotech

  • Directly relevant to teams in vaccines — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: vaccines

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Frontiers in Immunology study find?

The defective Treg/IL-35 axis appears to be a important component in ITP pathogenesis, identifying IL-35 as a promising therapeutic target.

What type of study is this?

It is a clinical study, published in Frontiers in Immunology in 2026. A history of vaccination within 1-4 weeks prior to onset was reported in 12.08% of patients, predominantly in the <1 year group (19.35%), whereas 24.58% had a recent history of respiratory infection, most frequently in the 3-6 years group (61.11%).

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1782560. PubMed ID: 41884844. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Yang Y, Lu D, Wu B et al.. Clinical characteristics and decreased CD4&lt;sup&gt;+&lt;/sup&gt;CD25&lt;sup&gt;+&lt;/sup&gt;Foxp3&lt;sup&gt;+&lt;/sup&gt; regulatory T cells and IL-35 in pediatric immune thrombocytopenia in a single center.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1782560.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/clinical-characteristics-and-decreased-cd4-lt-sup-gt-lt-sup-gt-cd25-lt-s-782560/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides